Danish biotech UNION adds program to prevent COVID-19 with intranasal delivery of niclosamide.
· Niclosamide is a potent inhibitor of SARS-CoV-2 with potency >40x higher than remdesivir as demonstrated by Institut Pasteur Korea
· The sinonasal cavity is considered a major site of early infection by SARS-CoV-2 and a major factor in transmission.
· Intranasal administration of niclosamide has been demonstrated to prevent fatal outcomes in a murine challenge model
· UNI91103 is a nasal spray pump delivering a concentrated niclosamide salt solution to the nasal cavity
· UNI91103 has been tested in 44 healthy volunteers with positive results
· UNI91103 is being prepared for clinical trials in subjects at high risk of contracting COVID-19
UNION therapeutics A/S completes dosing of healthy volunteers with UNI911 (inhaled niclosamide) for COVID-19
UNION has successfully completed inhalation dosing of 44 healthy volunteers, confirming the safety and tolerability of UNI911 UNION has utilized many years of experience with niclosamide to develop UNI911, a […]
UNION therapeutics A/S enters option agreement to acquire worldwide exclusive license for COVID-19 technologies developed by TFF Pharmaceuticals, Inc.
Niclosamide identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, with potency >40x higher than remdesivir UNION has advanced niclosamide-based program for COVID-19 (UNI911) to clinical development, currently […]
Spatial and Temporal Dynamics of SARS-CoV-2 in COVID-19 Patients – A Systematic Review and Meta-Analysis Published in EBioMedicine
Hellerup, Denmark: UNION therapeutics A/S today announced the publication of a systematic review and meta-analysis of COVID-19 patient’s presence and duration of SARS-CoV-2 virus published in EBioMedicine under The Lancet. The main […]
UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2
Candidates in the LEO PDE4 inhibitor compound series have demonstrated potential to become ‘best-in-class’ based on Phase 2 studies in psoriasis (oral) and atopic dermatitis (topical) PDE4 compound series strengthens […]
The Journal of Investigative Dermatology Publish UNION therapeutics’ Phase 2 Clinical Trial Results
ATx201 modulates biomarkers of cutaneous inflammation and skin barrier function in patients with moderate atopic dermatitis Analysis of safety data revealed ATx201 generally safe and well-tolerated in subjects with moderate […]
UNION receives approval from Danish Medicines Agency to initiate clinical study with niclosamide for treatment of COVID-19
Niclosamide has been identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, with potency >40x higher than remdesivir UNION has leveraged existing deep knowledge of niclosamide, derivatives and […]
UNION therapeutics launches COVID-19 program in collaboration with Institut Pasteur Korea
Niclosamide identified as the most potent FDA approved inhibitor of SARS-Cov-2 by Institut Pasteur Korea Potency of niclosamide >25x higher than chloroquine and >40x higher than remdesivir UNION has extensive […]
UNION initiates Phase 2b Dose-Ranging Study Evaluating ATx201 OINTMENT in Patients with Mild-to-Moderate Atopic Dermatitis
Multi-national, double-blinded, and vehicle-controlled study Study expected to enroll approximately 210 patients COPENHAGEN, Denmark: UNION therapeutics A/S (“UNION”), a privately held clinical stage pharmaceutical company dedicated to the discovery and […]
UNION achieves study completion milestone in UNI836 collaboration with Ceva Santé Animale S.A.
Copenhagen, Denmark: UNION therapeutics A/S announced today that a milestone was achieved in its UNI836 collaboration with Ceva Santé Animale S.A. The milestone was triggered by confirmation from Ceva of successful […]
